Trials Sponsors Conditions Drugs Pricing

Conditions

Refractory Systemic Juvenile Idiopathic Arthritis Systemic Juvenile Idiopathic Arthritis Systemic Juvenile Idiopathic Arthritis Associated Lung Disease

Outcome Measures

Primary Outcomes (1)

Overall Survival at 1 year
1-year post-transplant

Secondary Outcomes (6)

sJIA clinical remission
1-year post-transplant
Corticosteroid and biologic independence
Time Frame: 1-year post-transplant
Graft Failure
1-year post-transplant
Acute and Chronic Graft-Versus-Host Disease (GVHD)
1-year post-transplant
Transplant-Related Mortality
1-year post-transplant
+1 more secondary outcomes

Eligibility Criteria

AgeUp to 35 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64)

Sampling MethodNon-Probability Sample

Study Population

Children and young adults \<35 years of age with longstanding Systemic Juvenile Idiopathic Arthritis diagnosed in childhood will be enrolled if they meet the eligibility criteria below. Patients with Systemic Juvenile Idiopathic Arthritis associated lung disease are included and will be specifically evaluated.

You may qualify if:

Patients \<35 years of age are eligible, and participants must meet all the following criteria to be eligible for this study:

Sponsors & Collaborators

Children's Hospital Medical Center, Cincinnati
Otherlead

Study Sites (1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States

RECRUITING

Sharat Chandra, MDCONTACT513-636-5917 Sharat.Chandra@cchmc.org

Sharat Chandra, MDPRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Arthritis, Juvenile

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

Sharat Chandra, MD
Children's Hospital Medical Center, Cincinnati
PRINCIPAL INVESTIGATOR

Central Study Contacts

Sharat Chandra, MD

CONTACT

513-636-5917 Sharat.Chandra@cchmc.org

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 22, 2026

First Posted

September 29, 2026

Study Start

November 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

July 2031

Estimated

Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations